Hangzhou Center for Disease Control and Prevention (Hangzhou Health Supervision Institution), Hangzhou 310021, Zhejiang, China.
Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, China.
Biomed Environ Sci. 2024 Sep 20;37(9):993-1002. doi: 10.3967/bes2024.101.
This study aimed to investigate the prevalence of Epstein-Barr virus (EBV) infection in patients with and without cancer.
A total of 26,648 participants who underwent whole-blood EBV DNA (WBEBV) assays between January 1, 2020, and August 31, 2023, were included. The chi-square test was used for categorical data analysis, and R software was used to analyze the differences in EBV DNA load levels and the diagnostic capabilities of WBEBV.
Positive rates were 10.2% and 25.4% for healthy controls (HC) and patients, respectively. The positivity rate for EBV-associated neoplasms (EN) was the highest at 7.53%, followed by leukemia (Le) at 5.49%. The subgroup analysis showed that the positivity rate for abnormal proliferation or hyperplasia (APH) was 31.9%, followed by 30.5% for Le. The WBEBV of patients with transplants (TP), especially living-related transplants (LT), was the highest among all subgroups. WBEBV at diagnosis was used to differentiate between infectious mononucleosis (IM) and chronic active Epstein-Barr virus (CAEBV), with a sensitivity of 67.4% (95% confidence interval [ ]: 57.6-75.8) and specificity of 72% (95% : 63.3-79.3). We conclude that the prevalence of EBV infection is low in the healthy population in this region and that a high EBV load at baseline is more common in LT, IM, and Lymphocyte Leukemia (LL).
This study used a large-sample survey to characterize the prevalence of whole-blood EBV levels in various diseases, including the stages and subtypes. The EBV detection rate was higher in patients with malignant disease than in those with benign disease. Our study provides clinicians with baseline information regarding EBV-associated diseases.
本研究旨在调查患有癌症和不患有癌症的患者中 Epstein-Barr 病毒 (EBV) 感染的流行情况。
共纳入 2020 年 1 月 1 日至 2023 年 8 月 31 日期间接受全血 EBV DNA(WBEBV)检测的 26648 名参与者。采用卡方检验进行分类数据分析，使用 R 软件分析 EBV DNA 载量水平的差异和 WBEBV 的诊断能力。
健康对照组 (HC) 和患者的阳性率分别为 10.2%和 25.4%。EBV 相关肿瘤 (EN) 的阳性率最高，为 7.53%，其次是白血病 (Le)，为 5.49%。亚组分析显示，异常增殖或增生 (APH) 的阳性率为 31.9%，其次是 Le 为 30.5%。移植 (TP) 患者，尤其是活体相关移植 (LT) 患者的 WBEBV 最高。诊断时的 WBEBV 用于区分传染性单核细胞增多症 (IM) 和慢性活动性 EBV (CAEBV)，其敏感性为 67.4%（95%置信区间 [ ]：57.6-75.8），特异性为 72%（95%：63.3-79.3）。我们得出结论，在该地区的健康人群中 EBV 感染的流行率较低，基线时 EBV 载量较高的情况在 LT、IM 和淋巴细胞白血病 (LL) 中更为常见。
本研究使用大样本调查描述了各种疾病（包括阶段和亚型）中全血 EBV 水平的流行情况。患有恶性疾病的患者的 EBV 检出率高于患有良性疾病的患者。本研究为临床医生提供了 EBV 相关疾病的基线信息。
